立体定向体部放疗用于雄激素抑制下前列腺癌寡进展:TRAP试验主要终点分析
中位PFS为6.4个月(95%CI 5.9-11.4),达到主要终点;39%(95%CI 29-49)患者PFS>12个月。
要点
- TRAP试验达到主要终点:SBRT后中位PFS为6.4个月。
- 68%患者进展,41%在放疗后6个月内进展。
- 39%(95%CI 29-49)患者PFS延长超过12个月。
核心结论
- TRAP试验显示前列腺癌寡进展灶SBRT后中位PFS为6.4个月,达到主要终点。
研究设计与样本
- 入组条件为接受ARPI治疗且初始缓解后出现≤2个寡进展灶。
- SBRT剂量为30 Gy分5次(隔日)或36 Gy分6次每周(仅前列腺)。
主要发现
- 中位PFS为6.4个月(95%CI 5.9-11.4),估计39%(95%CI 29-49)患者PFS>12个月。
- 33例(41%)开始新治疗或死亡,至下次治疗或死亡的中位时间为27.0个月(95%CI 14.9-29.6)。
- 中位总生存为27.2个月(95%CI 24.7-36.6);SBRT后6个月内4例死亡,均与放疗无关。
关键数值与推荐
- 主要终点为SBRT局部控制寡进展灶能否将进一步进展延迟>4个月,从而推迟至下次治疗时间。
- 照射部位:骨59%、肺1%、淋巴结32%、前列腺7%;67%患者有1个寡进展灶。
临床怎么用
- 对于ARPI治疗中出现≤2个寡进展灶的去势抵抗性前列腺癌患者,SBRT可作为推迟下次治疗的策略。
- 进一步分析循环DNA和全身磁共振成像等生物标志物 panel 将有助于更好的患者选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal management of oligoprogressive prostate cancer while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiation therapy (SBRT) in this setting. The objective of this phase 2 prospective, nonrandomized, single-arm trial was to determine if local control of oligoprogressive disease with SBRT can delay further progression by >4 months, postponing time to next therapy. METHODS AND MATERIALS: Men with castration-resistant prostate cancer with ≤2 oligoprogressive sites developing on treatment with an ARPI, after initial response to therapy, were recruited. All patients were treated to a dose of 30 Gy in 5 fractions (alternate days) or 36 Gy in 6 fractions weekly (prostate only). RESULTS: Eighty-six men were recruited between October 2018 and February 2023. SBRT was delivered to 81 men. Mean age was 74 years. Most patients (67%) had 1 oligoprogressive disease lesion. Sites irradiated were bone (59%), lung (1%), lymph node (32%), and prostate (7%). Median follow-up was 22.9 months at the time of analysis. Fifty-five (68%) patients had progressed, 33 (41%) of patients progressed within 6 months of radiation therapy. Median progression-free survival (PFS) was 6.4 months (95% CI, 5.9-11.4). An estimated 39% (95% CI, 29-49) of patients have a prolonged PFS of > 12 months. Thirty-three (41%) of patients had started new treatment or died. Median time to either next treatment or death was 27.0 months (95% CI, 14.9-29.6). Median overall survival was 27.2 months (95% CI, 24.7-36.6). Four deaths occurred within 6 months of SBRT; none were related to radiation therapy treatment. CONCLUSIONS: The TRAP trial has demonstrated a median PFS of 6.4 months after SBRT for oligoprogression of prostate cancer, meeting the primary endpoint. Further analysis of biomarker panel including circulating DNA and whole-body magnetic resonance imaging will promote better patient selection.
引用
- Patel P, Dreibe S, Attard G, et al. Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40068778. doi:10.1016/j.ijrobp.2025.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。